Reduced-Dose Dabrafenib-Trametinib for BRAF V600E-Mutant Lung Adenocarcinoma in a Very Elderly Patient With ECOG PS 2
{{output}}
BRAF V600E mutations occur in approximately 1%-2% of non-small cell lung cancers (NSCLCs). Dabrafenib plus trametinib has demonstrated clinical efficacy in BRAF V600E-mutant NSCLC, although pyrexia frequently leads to treatment interruption. We report an 86-ye... ...
